Studies That Assessed Impact of Molecular PET/CT on SRT Planning
| Author | Year | PET/CT probe | Median PSA level (ng/mL) | Patients (n) | PET-positive | Extrapelvic PET-positive | Any SRT planning change | Radiotherapy considered futile |
| Souvatzoglou | 2011 | 11C-choline | 0.5 (range, 0.25–12.3) | 37 | 30% | 0% | 13.5% | 0% |
| Würschmidt | 2011 | 18F-choline | 1.9 (range, 0.42–4.8) | 16 | 87.5% | 6.5% | 81.5% | 6.5% |
| Ceci | 2014 | 11C-choline | 1.6 (range, 0.2–7.1) | 95 | 62% | 20% | 47.5% | 15.8% |
| Castelluci | 2014 | 11C-choline | 1.1 (range, 0.2–2) | 605 | 28.5% | 14.5% | 23% | 14.7% |
| Goldstein | 2017 | 11C-choline | 2 (range, 0.16–79) | 6 | NA | 33.5% | 0% | |
| Jereczek-Fossa | 2014 | 11C-choline | 1.1 (range, 0.2–16.2) | 55 | 51% | NA | 31% | NA |
| Shakespeare | 2015 | 68Ga-PSMA | 1.1 (range, 0.017–20.4) | 18 | NA | 46% | NA | |
| van Leeuwen | 2015 | 68Ga-PSMA | 0.2 (range, 0.05–0.99) | 70 | 54.5% | 5.5% | 34.5% | 7.1% |
| Sobol | 2016 | 11C-choline + multiparametric MRI | 2.3 (range, 1.4–5.5) | 260 | 77.5% | 26.5% | 51.5% | 26.5% |
| Sterzing | 2016 | 68Ga-PSMA | 2.8 (range, 0.16–113) | 42 | 59.5% | NA | 60.5% | NA |
| Albisinni | 2016 | 68Ga-PSMA | 2.2 (range, 0.72–6.7) | 48 | NA | 76% | NA | |
| Bluemel | 2016 | 68Ga-PSMA | 0.67 (range, 0.10–11.2) | 45 | 53.5% | 9% | 42% | 4.4% |
| Lamanna | 2017 | 18F-choline/11C-acetate | 1.9 (range, 0.3–3) | 9 | NA | 0% | 22% | 0% |
| Akin-Akintayo | 2017 | 18F-fluciclovine | 0.55 (range, 0.07–11.2) | 42 | 81% | 5% | 40.5% | 4.8% |
| Habl | 2017 | 68Ga-PSMA | 0.69 (range, 0.09–14.7) | 83 | 71% | 9.5% | 56.5% | 0% |
| Schiller | 2017 | 68Ga-PSMA | 0.71 (range, 0.12–14.7) | 31 | 1% | 3% | 87% | 0% |
| Calais | 2018 | 68Ga-PSMA | 0.48 (0.03–1.0) | 270 | 49% | 12% | 19% | 2.5% |
NA = not applicable.